PL2177536T3 - Przeciwciała przeciwko peptydowi beta-amyloidu - Google Patents

Przeciwciała przeciwko peptydowi beta-amyloidu

Info

Publication number
PL2177536T3
PL2177536T3 PL09178407T PL09178407T PL2177536T3 PL 2177536 T3 PL2177536 T3 PL 2177536T3 PL 09178407 T PL09178407 T PL 09178407T PL 09178407 T PL09178407 T PL 09178407T PL 2177536 T3 PL2177536 T3 PL 2177536T3
Authority
PL
Poland
Prior art keywords
antibodies against
beta peptide
against amyloid
amyloid
peptide
Prior art date
Application number
PL09178407T
Other languages
English (en)
Inventor
Stephen Anthony Burbidge
Jonathan Henry Ellis
Susannah K Ford
Volker Germaschewski
Umesh Kumar
Karen Louise Philpott
Peter Ernest Soden
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PL2177536T3 publication Critical patent/PL2177536T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL09178407T 2006-03-30 2007-03-27 Przeciwciała przeciwko peptydowi beta-amyloidu PL2177536T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78758806P 2006-03-30 2006-03-30
EP07727401A EP1996621B1 (en) 2006-03-30 2007-03-27 Antibodies against amyloid-beta peptide
EP09178407.4A EP2177536B1 (en) 2006-03-30 2007-03-27 Antibodies against amyloid-beta peptide

Publications (1)

Publication Number Publication Date
PL2177536T3 true PL2177536T3 (pl) 2014-11-28

Family

ID=38284050

Family Applications (2)

Application Number Title Priority Date Filing Date
PL07727401T PL1996621T3 (pl) 2006-03-30 2007-03-27 Przeciwciała przeciwko peptydowi beta amyloidu
PL09178407T PL2177536T3 (pl) 2006-03-30 2007-03-27 Przeciwciała przeciwko peptydowi beta-amyloidu

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL07727401T PL1996621T3 (pl) 2006-03-30 2007-03-27 Przeciwciała przeciwko peptydowi beta amyloidu

Country Status (32)

Country Link
US (3) US8227576B2 (pl)
EP (2) EP2177536B1 (pl)
JP (1) JP5103466B2 (pl)
KR (2) KR20120093400A (pl)
CN (2) CN101415729B (pl)
AR (1) AR060332A1 (pl)
AT (1) ATE451392T1 (pl)
AU (1) AU2007233831B2 (pl)
BR (1) BRPI0709246A2 (pl)
CA (1) CA2647808C (pl)
CR (1) CR10347A (pl)
CY (1) CY1109877T1 (pl)
DE (1) DE602007003703D1 (pl)
DK (2) DK2177536T3 (pl)
EA (1) EA015654B9 (pl)
ES (2) ES2484967T3 (pl)
HR (2) HRP20100115T1 (pl)
IL (1) IL193695A (pl)
JO (1) JO2576B1 (pl)
MA (1) MA30337B1 (pl)
MX (1) MX2008012483A (pl)
MY (1) MY149630A (pl)
NO (1) NO20083793L (pl)
NZ (1) NZ571038A (pl)
PE (1) PE20080181A1 (pl)
PL (2) PL1996621T3 (pl)
PT (2) PT1996621E (pl)
SI (2) SI1996621T1 (pl)
TW (1) TWI385179B (pl)
UA (1) UA94734C2 (pl)
WO (1) WO2007113172A2 (pl)
ZA (1) ZA200807911B (pl)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
WO2004060403A2 (en) 2003-01-06 2004-07-22 Angiochem Inc. Aprotinin and anglos as carriers across the blood-brain barrier
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
EP1838348B1 (en) 2004-12-15 2013-06-26 Janssen Alzheimer Immunotherapy Humanized amyloid beta antibodies for use in improving cognition
US7906625B2 (en) 2005-01-24 2011-03-15 Amgen Inc. Humanized anti-amyloid antibody
HRP20140240T4 (hr) 2005-11-30 2017-02-24 Abbvie Inc. Monoklonalna antitijela protiv amiloidnih beta proteina i njihova upotreba
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
EP2046833B9 (en) 2006-07-14 2014-02-19 AC Immune S.A. Humanized antibody against amyloid beta
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8323654B2 (en) 2007-05-14 2012-12-04 Medtronic, Inc. Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules
US7931899B2 (en) 2007-05-14 2011-04-26 Medtronic, Inc Humanized anti-amyloid beta antibodies
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
DK2182983T3 (da) * 2007-07-27 2014-07-14 Janssen Alzheimer Immunotherap Behandling af amyloidogene sygdomme med humaniserede anti-abeta antistoffer
ES2840725T3 (es) * 2007-08-20 2021-07-07 Glaxo Group Ltd Procedimiento de producción
GB0718737D0 (en) * 2007-09-25 2007-11-07 Glaxo Group Ltd Antibodies
AU2008311367B2 (en) 2007-10-05 2014-11-13 Ac Immune S.A. Use of anti-amyloid beta antibody in ocular diseases
US20100297013A1 (en) * 2007-10-05 2010-11-25 Andrea Pfeifer Humanized antibody
PT2592148T (pt) * 2007-10-12 2018-11-12 Hoffmann La Roche Expressão proteica de múltiplos ácidos nucleicos
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
EP2586797A3 (en) * 2007-11-27 2013-07-24 Medtronic, Inc. Humanized anti-amyloid beta antibodies
US8921523B2 (en) * 2007-12-11 2014-12-30 Glaxo Group Limited Humanized anti-beta-amyloid antibodies
EP2235058A2 (en) * 2007-12-21 2010-10-06 Amgen, Inc Anti-amyloid antibodies and uses thereof
EP2271323A2 (en) 2008-05-06 2011-01-12 Glaxo Group Limited Encapsulation of biologically active agents
CA2740316A1 (en) 2008-10-15 2010-04-22 Angiochem Inc. Conjugates of glp-1 agonists and uses thereof
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
CA2745524C (en) 2008-12-05 2020-06-09 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
MX2011011023A (es) 2009-04-20 2012-01-20 Angiochem Inc Tratamiento de cancer de ovarios usando un agente anti-cancer conjugado con un analogo de angiopep-2.
RU2012103240A (ru) * 2009-07-02 2013-08-10 Ангиокем Инк. Мультимерные пептидные конъюгаты и их применение
JP5934645B2 (ja) 2009-09-11 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体
EP2308897A1 (en) * 2009-10-09 2011-04-13 Pierre Fabre Medicament Chimeric antibodies specific for CD151 and use thereof in the treatment of cancer
NZ601117A (en) 2010-03-03 2014-06-27 Boehringer Ingelheim Int Biparatopic abeta binding polypeptides
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
WO2011149461A1 (en) * 2010-05-27 2011-12-01 Medtronic, Inc. Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules
EP2598882B1 (en) 2010-07-30 2017-07-26 AC Immune S.A. Safe and functional humanized antibodies for use in treating an amyloidosis
EP3533803B1 (en) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antibodies
CA2818173C (en) 2010-11-30 2022-05-03 Genentech, Inc. Low affinity blood brain barrier receptor antibodies and uses therefor
US20120244174A1 (en) 2011-01-31 2012-09-27 Intellect Neurosciences Inc. Treatment of tauopathies
EP2699596A4 (en) 2011-04-22 2015-01-14 Emergent Product Dev Seattle PROSTATE-SPECIFIC MEMBRANE-BINDING PROTEINS AND COMPOSITIONS AND METHOD THEREFOR
GB201113570D0 (en) 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
WO2013177062A2 (en) 2012-05-21 2013-11-28 Genentech, Inc. Methods for improving safety of blood-brain barrier transport
RU2509155C1 (ru) * 2012-10-25 2014-03-10 Федеральное государственное бюджетное учреждение науки Институт биохимии им. А.Н. Баха Российской академии наук Способ детекции белков в амилоидном состоянии и набор для детекции белков в амилоидном состоянии
WO2014203188A2 (en) 2013-06-19 2014-12-24 Glaxosmithkline Intellectual Property (No.2) Limited Novel assay
CN104558172A (zh) * 2015-01-04 2015-04-29 东南大学 一种针对β淀粉样蛋白的单域重链纳米抗体及其应用
EP3307326B9 (en) 2015-06-15 2021-02-24 Angiochem Inc. Methods for the treatment of leptomeningeal carcinomatosis
WO2017053469A2 (en) 2015-09-21 2017-03-30 Aptevo Research And Development Llc Cd3 binding polypeptides
WO2017072090A1 (en) * 2015-10-27 2017-05-04 Glaxosmithkline Intellectual Property Development Limited Combination therapy
US11530257B2 (en) * 2017-06-29 2022-12-20 The Trustees Of Columbia University In The City Of New York Chimeric antibodies for treatment of amyloid deposition diseases
US11382974B2 (en) 2017-08-01 2022-07-12 The Trustees Of Columbia University In The City Of New York Methods and compositions for treatment of amyloid deposition diseases
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa
US12018069B2 (en) 2018-06-28 2024-06-25 The Trustees Of Columbia University In The City Of New York Methods and compositions for imaging amyloid deposits
CN111094340B (zh) 2018-07-17 2022-11-22 江苏恒瑞医药股份有限公司 抗Abeta抗体、其抗原结合片段及应用
WO2020201828A1 (en) 2019-04-05 2020-10-08 Tauc3 Biologics Limited Anti-tauc3 antibodies and uses thereof
KR20230039734A (ko) 2020-07-23 2023-03-21 오타이르 프로테나 리미티드 항-Aβ 항체
TW202300517A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof
CN114591917B (zh) * 2022-05-07 2022-09-02 北京第一生物化学药业有限公司 产生结合β-淀粉样蛋白的抗体的杂交瘤细胞及其用途
CN114591918B (zh) * 2022-05-07 2022-07-26 北京第一生物化学药业有限公司 产生抗β-淀粉样蛋白抗体的杂交瘤细胞及其用途
KR102530956B1 (ko) * 2022-09-08 2023-05-11 주식회사 알츠코리아 아밀로이드 베타 유래 에피토프를 유효성분으로 포함하는 알츠하이머성 치매 백신 조성물 및 이의 용도
CN118638219B (zh) * 2024-08-19 2024-11-22 成都迈科康生物科技有限公司 一种抗轮状病毒vp8蛋白的抗体或其抗原结合片段、抗体偶联物、核酸、载体、细胞及其应用
WO2026082154A1 (en) * 2024-10-18 2026-04-23 Lepu Biopharma Co., Ltd. Anti-beta amyloid antibodies and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811517A (en) * 1992-01-27 1998-09-22 Icos Corporation ICAM-related protein variants
NZ337765A (en) * 1997-04-09 2001-09-28 Mindset Biopharmaceuticals Usa Recombinant antibodies having specificity for beta-amyloid N-terminus and C-terminus and use in treating Alzheimer's Disease
US7179892B2 (en) * 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
EP1133699A1 (en) * 1998-11-25 2001-09-19 Scios Inc. Prevention and treatment of amyloid-associated disorders
DE1257584T1 (de) * 2000-02-24 2003-05-28 Lilly Co Eli Humanisierte antikörper, die amyloid beta peptid demarkieren
ATE398177T1 (de) * 2000-11-03 2008-07-15 David Gladstone Inst Verfahren zur behandlung von erkrankungen im zusammenhang mit apoe
WO2004029629A1 (en) * 2002-09-27 2004-04-08 Janssen Pharmaceutica N.V. N-11 truncated amyloid-beta nomoclonal antibodies, compositions, methods and uses
ITTO20020867A1 (it) * 2002-10-08 2004-04-09 Pro Cord Spa Schienale di sedia.
US20040146512A1 (en) 2002-10-09 2004-07-29 Arnon Rosenthal Methods of treating Alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof

Also Published As

Publication number Publication date
WO2007113172A2 (en) 2007-10-11
SI1996621T1 (sl) 2010-04-30
CN103539857A (zh) 2014-01-29
JO2576B1 (en) 2011-02-27
CA2647808C (en) 2015-11-17
HRP20140618T1 (hr) 2014-08-15
KR20120093400A (ko) 2012-08-22
UA94734C2 (ru) 2011-06-10
ES2338179T3 (es) 2010-05-04
US20110142824A1 (en) 2011-06-16
PE20080181A1 (es) 2008-03-16
EA015654B1 (ru) 2011-10-31
TW200815466A (en) 2008-04-01
HK1122311A1 (en) 2009-05-15
CN101415729A (zh) 2009-04-22
EA200801842A1 (ru) 2009-02-27
SI2177536T1 (sl) 2014-09-30
AU2007233831A1 (en) 2007-10-11
NZ571038A (en) 2011-03-31
IL193695A0 (en) 2011-08-01
WO2007113172A3 (en) 2007-11-29
ZA200807911B (en) 2009-11-25
US20160024197A1 (en) 2016-01-28
CY1109877T1 (el) 2014-09-10
EP1996621A2 (en) 2008-12-03
DK1996621T3 (da) 2010-04-19
BRPI0709246A2 (pt) 2011-07-12
PL1996621T3 (pl) 2010-05-31
EP2177536A1 (en) 2010-04-21
TWI385179B (zh) 2013-02-11
JP5103466B2 (ja) 2012-12-19
EA015654B9 (ru) 2012-01-30
KR20080113273A (ko) 2008-12-29
AR060332A1 (es) 2008-06-11
MA30337B1 (fr) 2009-04-01
JP2009531380A (ja) 2009-09-03
CN101415729B (zh) 2013-09-04
PT2177536E (pt) 2014-08-22
EP2177536B1 (en) 2014-06-04
IL193695A (en) 2012-05-31
NO20083793L (no) 2008-10-13
KR101263294B1 (ko) 2013-06-04
ATE451392T1 (de) 2009-12-15
US20140050719A1 (en) 2014-02-20
AU2007233831B2 (en) 2013-02-14
HK1138015A1 (en) 2010-08-13
EP1996621B1 (en) 2009-12-09
DK2177536T3 (da) 2014-07-14
CR10347A (es) 2008-10-29
ES2484967T3 (es) 2014-08-12
US8227576B2 (en) 2012-07-24
DE602007003703D1 (de) 2010-01-21
CA2647808A1 (en) 2007-10-11
US9193784B2 (en) 2015-11-24
MX2008012483A (es) 2008-10-10
PT1996621E (pt) 2010-03-08
MY149630A (en) 2013-09-13
HRP20100115T1 (hr) 2010-04-30

Similar Documents

Publication Publication Date Title
IL193695A0 (en) Antibodies against amyloid-beta peptide
IL196806A0 (en) Anti-myostatin antibodies
IL189580A0 (en) Anti-myostatin antibodies
IL189579A0 (en) Anti-myostatin antibodies
IL194165A0 (en) Glycosylated antibodies
EP2017283A4 (en) Peptides
GB0615662D0 (en) Antibody
GB0611116D0 (en) Proteins
ZA200808647B (en) Glycosylated antibodies
GB0601976D0 (en) Proteins
GB0620735D0 (en) Proteins
GB0618748D0 (en) Peptide
IL197675A0 (en) Peptides
GB0605774D0 (en) Peptide
GB0612443D0 (en) Protein
GB0612623D0 (en) Proteins
GB0620304D0 (en) Protein
GB0614682D0 (en) Proteins
GB0607376D0 (en) Antibodies
GB0606276D0 (en) Antibodies
GB0625176D0 (en) Peptides
GB0609921D0 (en) Peptides
GB0618512D0 (en) Peptides
GB0609920D0 (en) Peptides
GB0616971D0 (en) Protein